Next Article in Journal
Microbial Biomarkers for Lung Cancer: Current Understandings and Limitations
Previous Article in Journal
Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
 
 
Article

Article Versions Notes

J. Clin. Med. 2022, 11(24), 7297; https://doi.org/10.3390/jcm11247297
Action Date Notes Link
article xml file uploaded 8 December 2022 14:47 CET Original file -
article xml uploaded. 8 December 2022 14:47 CET Update https://www.mdpi.com/2077-0383/11/24/7297/xml
article pdf uploaded. 8 December 2022 14:47 CET Version of Record https://www.mdpi.com/2077-0383/11/24/7297/pdf
article html file updated 8 December 2022 14:49 CET Original file -
article html file updated 4 March 2023 20:13 CET Update https://www.mdpi.com/2077-0383/11/24/7297/html
Back to TopTop